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Introduction: Methylene blue is receiving special interest in perioperative and intensive
care of patients with distributive shock due to its ability to block the action of nitric
oxide and to antagonize deep vasodilation. Objective: The objective is to illustrate the
use of the methylene blue, summarizing the perioperative management of a case with
secondary vasoplegic syndrome due to a norepinephrine refractory septic shock and the
response to methylene blue, reviewing the latest evidence of this therapeutic alternative.
In practice:We describe the case of a 60-year-old man, paraplegic, with septic shock
due to a long evolution decubitus pressure ulcer. After two hours of surgery, the
patient remained with hemodynamic deterioration despite high doses of vasopressin (3
IU/hour) and norepinephrine (2 µg/kg /min), therefore methylene blue was administered
with two intravenous bolus doses of 50 mg without adverse effects. After half an
hour hemodynamic improvement was evidenced, allowing to decrease norepinephrine
infusion and normalizing blood pressure. Finally, debridement of necrotic tissue,
amputation and disarticulation of left coxofemoral joint was performed with subsequent
transfer to the ICU and discharge to the spinal cord injury ward twenty eight days later.
Conclusions: As it has been demonstrated in our patient, methylene blue is a therapeutic
alternative to manage patients with persistent hypotension despite the use of various
vasopressors during the management of vasoplegic syndrome secondary to septic shock.
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1. Introduction
Septic shock is characterized by systemic inflammation that
evolves to a vasoplegic syndrome and it is associated with
hypotension, low systemic vascular resistance (SVR) and
increased requirements of fluids and vasopressors [1, 2].
Thereby the organism is unable to achieve adequate perfusion
of the target organs due to the lack of vascular tone and
vasodilation. This vasodilation is produced by an autonomic
dysregulation in the release of inflammatory mediators, such
as L-arginine which ends up producing an increase in nitric
oxide (NO) synthesis and cyclic guanosine monophosphate
(cGMP) for final activation of soluble guanylate cyclase
(sGC) in vascular smooth muscle [3–5].
Despite advances in vasopressor therapy, prolonged hy-
potension and poor tissue perfusion can lead to multiple organ
failure (MOF) and achieving 20 - 50% of mortality in the cases
of sepsis [1, 6].
Methylene blue has been used in perioperative and intensive
care of patients with distributive shock, septic and anaphylac-
tic, as well as cardiac surgery and liver transplantation [7–10].
This is due to its ability to antagonize the deep vasodilation
by inhibiting certain cytokines of endothelial damage such
as nitric oxide synthase (iNOS) and sGC, thereby producing
blockage in both the synthesis and mode of action of NO.
The aim is to describe a case of a secondary vasoplegic
syndrome due to norepinephrine refractory septic shock and
the response to methylene blue, reviewing the latest evidence
of this therapeutic alternative.
2. In practice
We present the clinical case of a 60-year-old man (weight 98
Kg), paraplegic due to a spinal cord injury 20 years ago, with
unknown drug allergies and with a history of hypertension
treatment with nebivolol, candesartan, mirtazapine and alfu-
zosin. The patient went to the emergency department for a
long evolution decubitus pressure ulcer with a necrotic slough
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of about 40 cm in sacrum and trochanter (Fig. 1). After
performing blood test, a leukocytosis 21,900 /µL, renal failure
with creatinine 2.26 and K+ 6.3 mmol/L and procalcitonin >
40 ng/ml were evidenced, all compatible with septic features.
F IGURE 1. Decubitus Pressure Ulcer.
Thus treatment of intravenous antibiotic therapy with
imipenem and vancomycin was started, and after an
assessment done by the plastic surgery service an urgent
surgical treatment was finally decided.
At the entrance to the operating room the blood pressure
was 60/30 mmHg so treatment was initiated with crystal-
loid and colloid to expand intravascular volume and 200 µg
phenylephrine and norepinephrine infusion of 0.5 µg/kg /min.
Anesthesia was induced with midazolam 2 mg, fentanyl 250
µg, propofol 150 mg and rocuronium 80 mg and it remained
with sevoflurane 1 - 2%, continuous infusion of rocuronium 25
mg/h, fentanyl 50 µg/h bolus and continuous infusion remifen-
tanil 0.03 - 0.15 µg/kg /min. Central venous access at the right
jugular was channeled, and invasive arterial blood pressure
and continuos cardiac output monitoring through access of the
left radial artery was performed. Mechanical ventilation was
started with inspired fraction of 50%, a volume 550 ml with a
rate of 15 to 17 breaths per minute and positive end-expiratory
pressure (PEEP) of 7 cm H2O maintaining arterial saturations
above of 95%.
At the beginning of the surgery the following hemodynamic
parameters and arterial blood gases were observed: pH 7.12,
pCO2 53 mmHg, K+ 6.2 mmol / L, lactate 3.8 mmol/L and
Hb 9.3 g/dL; blood pressure was maintained at 70/40 mmHg,
heart rate at 110 beats/min, EtCO2 at 50 mmHg, SpO2 at 95%
and central venous pressure (CVP) at 16 mmHg.
After two hours of evolution the patient remained with
hemodynamic deterioration with blood pressure of 70/30
mmHg despite of administration of 3 IU/hour of vasopressin
infusion and giving a maximum dose of norepinephrine at
2 µg/kg /min, so it was decided to use methylene blue (Fig.
2). Methylene blue was administered with an interval of 20
minutes, two intravenous bolus doses of 50 mg up to a total
of 1 mg/kg without adverse effects of interest, except for a
brief interference in the accuracy of the pulse oximetry and
greenish staining urine (Fig. 3).
After half an hour of the methylene blue administration,
hemodynamic improvement was evidenced and it was
maintained over time for 3 hours allowing to decrease
norepinephrine infusion to 1 µg/kg /min and normalizing
blood pressure at 100/70 mmHg.
During seven hours of surgery crystalloid 4500 ml and
colloid 1500 ml were administered, with an approximate blood
loss of 1700 ml. Total diuresis was maintained at 2450 ml
under furosemide administration of 10 mg/hour. Furthermore
it was necessary 7 red blood cell concentrates and 2 platelets
pool maintaining at the end of the surgery a hematocrit of 17
% and haemoglobin of 5.3 g/dL.
Severe metabolic acidosis (pH 7.12) and hyperkalemia (K+
6.2 mmol/L) were managed with bicarbonate total dose of
500 ml (1 molar) and a 4 g of calcium gluconate. Control
coagulopathywas achieved (international normalized ratio 1.5,
prothrombin activity 42%, fibrinogen derivative 10 g/L) using
20 mg of vitamin K, tranexamic acid 1.5 g and a unit of fresh
frozen plasma (FFP).
During the surgery, the debridement of the necrotic tissue
that spread from the skin to internal compartments of the
gluteus, thigh and left leg with involvement of the coxofemoral
joint, rectal wall, and external anal sphincter was performed
(Fig. 4).
Finally, with the collaboration of Traumatology Service an
amputation and disarticulation of left coxofemoral joint and
musculocutaneous reconstruction using the anterior compart-
ment of thigh was carried out.
After completing the surgery the patient was transferred to
the ICU and in the first post-surgery hours the patient main-
tained a severe septic shock with MOF and severe metabolic
acidosis so that a continuous venovenous hemodiafiltration
was started. Twenty-eight days later the patient was discharged
from the ICU to the spinal cord injury ward managed by the
Plastic Surgery Service.
3. Discussion
One of the causes of the resistance to the use of norepinephrine
and vasopressin in our patient may be the chronic treatment
with alfuzosin and nebivolol. Alfuzosin is a drug used
for benign prostatic hyperplasia that blocks the effect of
α1 adrenergic receptors, lowering blood pressure by post-
synaptic blockade, inhibiting the vasoconstrictive effect
of norepinephrine [12]. On the other hand, nebivolol is
a selective third-generation beta-blocker against beta-1
receptors with vasodilation effects mediated by the release of
NO [13].
Although methylene blue is not new, since Schneider et al.
[14] first described it in sepsis shock patients, the data of its
usage are limited [15]. Most of the observational studies and
only two existing clinical trials in the literature to date (Kirov
et al., including 20 patients [16] and Memis et al., including 30
patients [17]) evidence a significant increase in mean arterial
pressure (MAP), pulmonary artery pressure, and SVR after
use.
Other observational studies as Andresen et al [18] further
showed a decrease in serum lactate at 24 hours due to selective
increase of mesenteric flow. Juffermans et al. [19] con-
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F IGURE 2. Use of Vasoactive Drugs and Hemodynamic Parameters During Anesthesia in the Operating Room.
Phenylephrine, α1 adrenergic agonist; NE, norepinephrine α1 α2 and β1 adrenergic agonist; vasopressin, V1 vasopressor and
V2 antidiuretic effect; MB, methylene blue inhibits nitric oxide synthase (iNOS) and soluble guanylate cyclase (sGC).
F IGURE 3. Central Methylene Blue Bolus.
cluded that methylene blue causes a transient effect and dose-
dependent increasing cardiac output, MAP and SVR, although
like Zhang et al. [20] demonstrated that high doses of methy-
lene blue (5 to 20 mg/kg) worsened myocardial depression,
and from 7 mg/kg may even compromise splanchnic perfusion
[19].
If methylene blue is compared during sepsis with other NO
inhibitors, vasopressin decreases cardiac output while methy-
lene blue does not change or even increases cardiac output
[1, 11, 21].
Although the delayed onset of the hemodynamic response
of methylene blue is transient and does not modify the natural
history of septic shock, it allows a dose reduction of vasopres-
F IGURE 4. Amputation and Disarticulation of Left
Coxofemoral Joint andMusculocutaneous Reconstruction.
sors, inotropic support, fluid therapy and blood transfusions
thereby reducing renal, respiratory complications and acceler-
ating postoperative recovery, having described a reduction in
mortality of up to 21.4% in patients with vasoplegic syndrome
[1, 22–24].
The dosing schedule is a single intravenous dose of methy-
lene blue 1 to 2 mg/kg, and a second dose can be repeated
after 20 minutes and a continuous infusion at 2 mg/kg within 6
hours in patients who persists the hypotension after at least an
infusion of 0.5 µg/kg /min of norepinephrine [1, 3, 23].
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4. Conclusions
It is relevant tomention that it should be early administered and
not be administered only as a rescue measure since its effect
and usefulness diminish significantly once MOF is has been
established [1, 22].
Although more randomized studies are needed to identify
its exact role in septic shock, as it has been demonstrated in
our patient, methylene blue is already considered as a rescue,
adjuvant and second-line therapeutic alternative to manage
patients with persistent hypotension despite the use of various
vasopressors during the perioperative management of the va-
soplegic syndrome secondary to septic shock while etiological
treatment is performed.
ACKNOWLEDGEMENTS
Other contributing authors from the Research Group in
Anesthesia, Resuscitation, and Perioperative Medicine of
Institute for Health Research Aragón (IIS Aragón) for this
study are: Jesús Gil-Bona, Fernando Martínez-Ubieto, Luis
Alfonso Muñoz-Rodríguez, Guillermo Pérez-Navarro, Berta
Pérez-Otal, Natividad Quesada-Gimeno, Lucía Tardós-
Ascaso, Sara Visiedo-Sanchez.
CONFLICTS OF INTEREST
There is no conflict of interest on the part of any author.
AUTOR CONTRIBUTION
Each author has participated sufficiently in the work to take
public responsibility for appropriate portions of the content.
INFORMED CONSENT STATEMENT
Informed written consent was obtained from the patient for
publication of this report and any accompanying images.
ETHICAL APPROVAL
The study was approved by the Clinical Research Ethics Com-
mittee of the Miguel Servet University Hospital in Zaragoza.
SUPPORTIVE FOUNDATIONS
Supported by ERDF (FEDER) Operational Programme
of Institute for Health Research Aragón (IIS Aragón) No.
B26_17D.
REFERENCES
[1] Hosseinian L, Weiner M, Levin MA, et al. Methylene Blue: Magic Bullet
for Vasoplegia?. Anesth Analg. 2016;122:194-201.
[2] Shanmugam G. Vasoplegic syndrome-the role of methylene blue. Eur J
Cardiothorac Surg. 2005;28:705-710.
[3] Carrillo-Esper R, Sosa-García JO, Carrillo-Córdova JR, et al. Azul de
metileno para el manejo del choque séptico refractario a vasopresores.
Rev Mex Anest. 2010;33:214-219.
[4] Manghelli J, Brown L, Tadros HB,et al. A reminder of methylene blue’s
effectiveness in treating vasoplegic syndrome after on-pump cardiac
surgery. Tex Heart Inst J. 2015;42:491–494.
[5] Evora PR. Methylene Blue Is a Guanylate Cyclase Inhibitor That Does
Not Interfere with Nitric Oxide Synthesis. Tex Heart Inst J. 2016;43:103.
[6] Huet O, Chin-Dustin J. Septic shock: desperately seeking treatment. Clin
Sci. 2014;126:31–39.
[7] Bauer CS, Vadas P, Kelly KJ. Methylene blue for the treatment
of refractory anaphylaxis without hypotension. Am J Emerg Med.
2013;31:264.e3-5.
[8] Lo JC, Darracq MA, Clark RF. A review of methylene blue treatment for
cardiovascular collapse. J Emerg Med. 2014;46:670-79.
[9] Evora PR. Methylene Blue and Cardiovascular Collapse. J Emerg Med.
2016;50:126-127.
[10] Pasin L, Umbrello M, Greco T, et al. Methylene blue as a vasopressor: a
meta-analysis of randomised trials. Crit Care Resusc. 2013;15:42–48.
[11] Stocche RM, Garcia LV, Reis MP, et al. Methylene blue to treat
anaphylaxis during anesthesia: case report. Rev Bras Anestesiol.
2004;54:809-814.
[12] Mercanoglu G, Semen O. Nitric oxide mediated the effects of nebivolol
in cardiorenal syndrome. Iran J Basic Med Sci. 2019;22:1314-1324.
[13] In Duk O, Eunsil S, Jong-Mi J, et al. Use of methylene blue in vasoplegic
syndrome that developed during non-cardiac surgery: A case report.
Anesth Pain Med. 2019;14:460-464.
[14] Schneider F, Lutun P, Hasselmann M, et al. Methylene blue increases
systemic vascular resistance in human septic shock. Preliminary observa-
tions. Intensive Care Med. 1992;18:309-311.
[15] Paciullo CA, Mcmahon horner D, Hatton KW, et al. Methylene blue for
the treatment of septic shock. Pharmacotherapy. 2010;30:702-715.
[16] Kirov MY, Evgenov OV, Evgenov NV, et al. Infusion of methylene blue
in human septic shock: a pilot, randomized, controlled study. Crit Care
Med .2001;29:1860–1867.
[17] Memis D, Karamanlioglu B, Yuksel M, et al. The influence of methylene
blue infusion on cytokine levels during severe sepsis. Anaesth Intensive
Care. 2002;30:755–762.
[18] Andresen M, Dougnac A, Díaz O, et al. Use of methylene blue in patients
with refractory septic shock: impact on hemodynamics and gas exchange.
J Crit Care. 1998;13:164–168.
[19] Juffermans NP, Vervloet MG, Daemen-Gubbels CR, et al. A dose
finding study of methylene blue to inhibit nitric oxide actions in the
hemodynamics of human septic shock. Nitric Oxide. 2010;22:275–280.
[20] Zhang H, Rogiers P, Preiser JC, et al. Effects of methylene blue on oxygen
availability and regional blood flow during endotoxic shock. Crit Care
Med. 1995;25:1711-1721.
[21] Lavigne D. Vasopressin and methylene blue: alternate therapies in
vasodilatory shock. Semin Cardiothorac Vasc Anesth. 2010;14:186-189.
[22] Carrillo-Esper R, Nuñez-Monroy FN, Alvarado-Martinez C. Azul de
metileno en choque séptico refractario. Rev Asoc Mex Med Crit Ter
Int.1999;13:28-35.
[23] Mccartney SL, Duce L, Ghadimi K. Intraoperative vasoplegia: methylene
blue to the rescue!. Curr Opin Anaesthesiol. 2018;31:43-49.
[24] Booth AT, Melmer PD, Tribble B, et al. Methylene Blue for Vasoplegic
Syndrome. Heart Surg Forum. 2017;20:E234-E238.
How to cite this article: Cristian Aragón-Benedí, Ana Pascual-
Bellosta, Sonia Ortega-Lucea, Luisa Lacosta-Torrijos, Teresa
Jiménez-Bernadó, Javier Martínez-Ubieto, et al. Methylene blue?
Therapeutic Alternative in the Management of Septic Shock
Refractory to Norepinephrine. Signa Vitae. 2020;16(2):199-202.
doi:10.22514/sv.2020.16.0063.
